Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel

BACKGROUND: The first FDA-approved test to assess risk for acute kidney injury (AKI), [TIMP-2]•[IGFBP7], is clinically available in many parts of the world, including the USA and Europe. We sought to understand how the test is currently being used clinically. METHODS: We invited a group of experts k...

Descripción completa

Detalles Bibliográficos
Autores principales: Guzzi, Louis M., Bergler, Tobias, Binnall, Brian, Engelman, Daniel T., Forni, Lui, Germain, Michael J., Gluck, Eric, Göcze, Ivan, Joannidis, Michael, Koyner, Jay L., Reddy, V. Seenu, Rimmelé, Thomas, Ronco, Claudio, Textoris, Julien, Zarbock, Alexander, Kellum, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585126/
https://www.ncbi.nlm.nih.gov/pubmed/31221200
http://dx.doi.org/10.1186/s13054-019-2504-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585126/
https://www.ncbi.nlm.nih.gov/pubmed/31221200
http://dx.doi.org/10.1186/s13054-019-2504-8

Ejemplares similares